Acarix

Acarix EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Acarix (ACARIX.ST) as of Nov 12, 2026 is -6.47. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -4.40 — a change of 47.27% (lower).

EV/FCF

-6.47

YoY

47.27%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Acarix is 2025 -6.47 . EV/FCF (Enterprise Value to Free Cash Flow) of Acarix was 2024 -4.40 . It decreases by 47.27% lower compared to the previous year.

The Acarix EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-7.02 SEK
Jan 1, 2019
-6.36 SEK
Jan 1, 2020
-7.45 SEK
Jan 1, 2021
-6.68 SEK
Jan 1, 2022
-4.34 SEK
Jan 1, 2023
-3.70 SEK
Jan 1, 2024
-4.40 SEK
Jan 1, 2025
-6.47 SEK
The Acarix EV/FCF history
YEAREV/FCFYoY
-6.47+47.27%
-4.40+18.76%
-3.70-14.65%
-4.34-35.11%
-6.68-10.32%
-7.45+17.18%
-6.36-9.44%
-7.02+31.18%
-5.35-40.27%
-8.96-59.38%
-22.07+45.97%
-15.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acarix Stock analysis

What does Acarix do? Acarix AB generates revenue through the sale of its primary medical device, the CADScor System, which utilizes phonocardiography for coronary artery disease monitoring. The system is designed for use by physicians, nurses, and laboratory technicians in clinical settings, featuring a chest patch with a recording head positioned at the fourth left intercostal space and a sensor on the sternum. Patients undergo a two-minute heart sound recording guided by audio cues and display instructions, after which the CAD-score is calculated and displayed for diagnostic purposes. The company's business model relies on direct sales of the CADScor System to healthcare providers, including hospitals and diagnostic laboratories, where the device is used for non-invasive rule-out diagnosis of coronary artery disease. The system's unique phonocardiography technique and algorithm-based scoring provide a streamlined diagnostic process, reducing the need for more invasive procedures and appealing to medical professionals seeking efficient diagnostic tools. Acarix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acarix stock

EV/FCF (Enterprise Value to Free Cash Flow) of Acarix is -6.47 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Acarix changed from -4.40 to -6.47, representing a 47.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Acarix since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Acarix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Acarix

All Key Metrics — Acarix